Testosterone oral - TesoRx
Alternative Names: CDGP therapy - TesoRx; TSX-002Latest Information Update: 19 Dec 2023
At a glance
- Originator Western University of Health Sciences
- Developer TesoRx
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Testosterone congener stimulants; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Hypogonadism
Most Recent Events
- 19 Dec 2023 Discontinued - Phase-II for Hypogonadism (In adolescents) in USA (PO) (TesoRx pipeline, December 2023)
- 09 Sep 2020 Phase-II development is ongoing in Hypogonadism (In adolescents) in USA (PO) before September 2020 (TesoRx pipeline, September 2020)
- 01 Dec 2017 A phase II study in constitutional delay in growth and puberty is planned for adolescent males in Japan in 2018